Ligand Pharmaceuticals | LGND - Current Liabilities

Stock Price
231.27
Daily Change
2.79 1.22%
Monthly
13.06%
Yearly
114.00%
Q2 Forecast
226.32

Ligand Pharmaceuticals reported $37.45M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
Agenus USD 323.49M 36.36M Dec/2025
Amgen USD 25.49B 3.7B Dec/2025
Anika Therapeutics USD 21.91M 2.82M Dec/2025
Arrowhead Research USD 347.42M 151.94M Dec/2025
Baxter International USD 2.97B 805M Dec/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Eli Lilly USD 35.23B 4.91B Dec/2025
Enanta Pharmaceuticals USD 44.73M 3.83M Dec/2025
Enviri Corporation USD 634.02M 5.4M Dec/2025
Gilead Sciences USD 11.81B 485M Dec/2025
GlaxoSmithKline GBP 21.39B 57M Dec/2025
Glaxosmithkline GBP 28.82B 144.79M Dec/2025
Heron Therapeutics USD 96.1M 6.39M Dec/2025
Insmed USD 468.87M 51.66M Dec/2025
Intrexon USD 23.02M 38K Jun/2024
Ionis Pharmaceuticals USD 783M 120.46M Dec/2025
Karyopharm Therapeutics USD 92.06M 4.9M Dec/2025
Ligand Pharmaceuticals USD 37.45M 6.91M Dec/2025
MacroGenics USD 43.11M 1.36M Dec/2025
Merck USD 28.63B 2.59B Sep/2025
Pacira USD 120.59M 13.51M Dec/2025
Pfizer USD 36.6B 1.13B Sep/2025
Rigel Pharmaceuticals USD 94.4M 7.76M Sep/2025
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Veracyte USD 59.94M 12.22M Dec/2025